Word

SWANBIO THERAPEUTICS

Status

Pending

Status Code

688

Status Date

Tuesday, February 27, 2024

Serial Number

97187198

Mark Type

4000

Filing Date

Thursday, December 23, 2021

Published for Opposition

Tuesday, January 2, 2024

Trademark Owner History

SwanBio Therapeutics Limited - Owner At Publication

Classifications

5 Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders; none of the foregoing constituting reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays

42 Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development; none of the foregoing relating to reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays

SWAN BIO THERAPEUTICS

Trademark Events

Feb 27, 2024

Noa E-Mailed - Sou Required From Applicant

Jan 2, 2024

Official Gazette Publication Confirmation E-Mailed

Jan 2, 2024

Published For Opposition

Dec 13, 2023

Notification Of Notice Of Publication E-Mailed

Nov 28, 2023

Approved For Pub - Principal Register

Sep 8, 2023

Teas/Email Correspondence Entered

Sep 8, 2023

Correspondence Received In Law Office

Sep 8, 2023

Teas Response To Office Action Received

Jun 8, 2023

Notification Of Non-Final Action E-Mailed

Jun 8, 2023

Non-Final Action E-Mailed

Jun 8, 2023

Non-Final Action Written

Apr 11, 2023

Teas/Email Correspondence Entered

Apr 10, 2023

Correspondence Received In Law Office

Apr 10, 2023

Teas Response To Office Action Received

Oct 11, 2022

Notification Of Non-Final Action E-Mailed

Oct 11, 2022

Non-Final Action E-Mailed

Oct 11, 2022

Non-Final Action Written

Sep 27, 2022

Assigned To Examiner

Dec 30, 2021

New Application Office Supplied Data Entered